NDAORALCAPSULE, DELAYED REL PELLETS
Approved
Sep 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
DEPAKOTE (divalproex sodium) by AbbVie is tract. Approved for bipolar disorder, epilepsy, migraine. First approved in 1989.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEPAKOTE (divalproex sodium) is an oral anticonvulsant approved in 1989 with a mechanism of action believed to involve increased brain GABA concentrations. It treats a broad range of indications including epilepsy, bipolar disorder, migraine, and various psychiatric conditions. The drug's multi-indication profile reflects decades of off-label use and clinical validation across CNS disorders.
$0.277MPart D
LOE ApproachingDeclining
Declining franchise with modest Medicare utilization signals maturity; legacy product team focus shifts toward lifecycle management and generic transition planning.
Mechanism of Action
tract. The mechanisms by which valproate exerts its therapeutic effects have not been established. It has been suggested that its activity in epilepsy is related to increased brain concentrations of gamma-aminobutyric acid (GABA).
Indications (3)
Worked on DEPAKOTE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.